Sector News

Cancer player Nordic Nanovector stokes takeover talk

February 21, 2017
Life sciences

Nordic Nanovector CEO Luigi Costa has talked up the level of third-party interest in non-Hodgkin lymphoma (NHL) candidate Betalutin. Costa claimed the level of interest in the asset is growing as clinical data accumulates, triggering a double-digit jump in Nanovector’s stock price.

Nanovector is now up 670% over the past year. The sharp rise covers a period in which Nanovector has bounced back from a filing-delaying R&D rejig and cases of reversible thrombocytopenia and neutropenia to advanced to the cusp of a pivotal study of its CD37-targeting antibody-radionuclide conjugate. Along the way, Nanovector has released data from its phase 1/2 trial, spurring the interest of investors and, according to Costa, the attention of possible partners and buyers.

“We talk a lot with companies, and as the data improves and the company develops, the more interest we have, that’s for sure,” Costa told Reuters.

Nanovector is up more than 10% this week on the strength of the comment, although at this stage Costa is yet to commit to seeking a buyer, let alone find a company willing to meet the asking price. Pushing ahead with development and potentially commercialization of Betalutin solo or in a partnership are both still options.

“[We will be] opportunistic about this,” Costa said.

The task of deciding the best path forward will become more of a priority if Betalutin can clear the clinical hurdles it faces. With the phase 1/2 trial reporting overall and complete response rates of 63% and 29% in 35 heavily pretreated patients with relapsed NHL last year, the asset is on the cusp of advancing to the next stage of development.

Nanovector raised NOK 499 million ($60 million) to fund development late last year, 20 months after it pulled off a NOK 575 million IPO, one of the larger biotech listings seen in Europe in 2015. Those financings have set Nanovector up to embark on a development path it sees leading to a filing for FDA approval in third-line follicular lymphoma in the first half of 2019 and have the drug on the market before the decade is over.

“Our timeline is based on the assumption that the FDA will grant us a breakthrough therapy designation and accelerated approval,” Costa said.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.